Aasne A.
- Country
- Norway
- Department
- Norwegian Porphyria Centre
Research Overview
- Long-term Safety and Tolerability Evaluation of Oral Dersimelagon (MT-7117) in Erythropoietic Protoporphyria and X-Linked Protoporphyria Patients
- APOLLO: A Randomized, Double-Blind, Placebo-Controlled Study of Bitopertin to Evaluate the Efficacy, Safety, and Tolerability in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)
- An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Bitopertin in Participants with Erythropoietic Protoporphyria or X-Linked Protoporphyria
Data & Insights
Has run more than one trial at 12 of 23 partner sites.
Specializations
Porphyria Disorders and Metabolic Diseases
This investigator demonstrates specialized expertise in the diagnosis, management, and treatment of porphyria disorders, a group of rare metabolic conditions affecting heme biosynthesis. The clinical focus encompasses various forms of porphyria, with particular attention to their acute and chronic manifestations. The investigator's work addresses the complex therapeutic challenges associated with these inherited metabolic disorders, which can present with severe neurological, cutaneous, and systemic complications.
- Acute and chronic porphyria management
- Heme biosynthesis pathway disorders
- Rare metabolic disease therapeutics
The investigator's involvement in advancing treatment options for patients with porphyria reflects a commitment to addressing unmet medical needs in this challenging field of rare disease medicine.
Hepatic and Systemic Complications
Research activities extend to understanding and managing the hepatic manifestations associated with porphyria and related metabolic conditions. The investigator focuses on the systemic impact of these disorders, particularly their effects on liver function and overall metabolic homeostasis. This work encompasses the evaluation of therapeutic interventions aimed at reducing disease burden and preventing serious complications such as hepatic dysfunction and progression to more severe hepatic pathology.
- Liver disease in metabolic disorders
- Prevention of hepatic complications
- Systemic manifestations of porphyria
The therapeutic approach emphasizes comprehensive management strategies that address both the underlying metabolic defect and its downstream effects on hepatic and systemic health.
Neurological Manifestations of Metabolic Disorders
A significant area of clinical interest involves the neurological complications arising from porphyria and related metabolic conditions. The investigator's work addresses acute neurovisceral crises, chronic neuropathic symptoms, and the prevention of potentially life-threatening neurological attacks. This includes evaluation of therapeutic strategies to reduce the frequency and severity of acute porphyric attacks, which can present with severe abdominal pain, neuropsychiatric symptoms, and peripheral neuropathy.
- Acute neurovisceral attacks
- Chronic neuropathic pain management
- Neuropsychiatric manifestations
The clinical focus encompasses both acute intervention strategies and long-term preventive approaches to minimize neurological morbidity in affected patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.